Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI -0.03%80 EV-to-EBIT is 49.73 as of Aug. 16, 2026. GuruFocus rates SMTI with a GF Score™ of 80/100 and a GF Value™ of $43.23 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 84.29% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sanara MedTech's Enterprise Value for the quarter that ended in Jun. 2026 was $250.0 Mil.
Sanara MedTech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech EV-to-EBIT Related Terms
Sanara MedTech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sanara MedTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's EV-to-EBIT falls into.
Sanara MedTech's current Enterprise Value is $346.9 Mil.
Sanara MedTech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech (SMTI) has a EV-to-EBIT of 49.73 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #397 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 84.3%.
Is Sanara MedTech's EV-to-EBIT too high?
Sanara MedTech's current EV-to-EBIT is 49.73. The Medical Devices & Instruments industry median EV-to-EBIT is 19.35. Sanara MedTech's value of 49.73 is 157% above this industry median. Based on the distribution chart, Sanara MedTech ranks #397 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's EV-to-EBIT compare to UTMD and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #397 out of 471 companies for EV-to-EBIT. This places Sanara MedTech in the lower half of its industry. The industry median EV-to-EBIT is 19.35. Sanara MedTech's value of 49.73 is 157% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.35, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current EV-to-EBIT of 49.73 is 157% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current EV-to-EBIT is 49.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $43.23, compared to a current price of $34.15 — trading 21% below its estimated fair value. The current EV-to-EBIT is 49.73 and 157% above the Medical Devices & Instruments industry median of 19.35. Sanara MedTech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current EV-to-EBIT is 49.73 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $34.15 is trading 21% below its estimated GF Value™ of $43.23.
GuruFocus considers Sanara MedTech to be Modestly Undervalued.
Key valuation signals for SMTI:
EV-to-EBIT: 49.73
GF Value™: $43.23 vs. price of $34.15 (21% below fair value)
Industry Position: 157% above the Medical Devices & Instruments median (#397 of 471)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
80GF Score
Get the complete analysis for SMTI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
